Drug treatments for obesity: orlistat, sibutramine, and rimonabant. (Q30359088)

20 June 2017

1 reference

title

Drug treatments for obesity: orlistat, sibutramine, and rimonabant. (English)

1 reference

20 June 2017

0 references

1 reference

Raj S Padwal

1

1 reference

PubMed ID

17208644

20 June 2017

Sumit R Majumdar

series ordinal

2

1 reference

PubMed ID

17208644

20 June 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

20 June 2017

1 reference

20 June 2017

369

1 reference

20 June 2017

71-77

1 reference

20 June 2017

9555

1 reference

Central nervous system control of food intake

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Changes in energy expenditure resulting from altered body weight.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

1 reference

7 January 2021

The National Weight Control Registry: is it useful in helping deal with our obesity epidemic?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Addressing the unmet medical need for safe and effective weight loss therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Current and investigational antiobesity agents and obesity therapeutic treatment targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Pharmacotherapy for obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

1 reference

7 January 2021

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Orlistat enhances warfarin effect

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Sibutramine. A review of its contribution to the management of obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

How does sibutramine work?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Randomized trial of lifestyle modification and pharmacotherapy for obesity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

A benefit-risk assessment of sibutramine in the management of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The endocannabinoid system and its therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The endocannabinoid system: a general view and latest additions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Endocannabinoid control of food intake and energy balance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Cannabinoid physiology and pharmacology: 30 years of progress.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Cannabinoid receptors as therapeutic targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Endocannabinoids and the regulation of body fat: the smoke is clearing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The endocannabinoid system and the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Rimonabant: the first therapeutically relevant cannabinoid antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Rimonabant--a selective CB1 antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Increased severity of stroke in CB1 cannabinoid receptor knock-out mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Trends in obesity and overweight-related office visits and drug prescriptions in Canada, 1998 to 2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Obesity market overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

Obesity and the regulation of energy balance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2960033-6

7 January 2021

10.1016/S0140-6736(07)60033-6

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

17208644